Country Access Report
Italy maintains a largely prohibition‑based approach to classical psychedelics: most classic hallucinogens (psilocybin, MDMA, mescaline, DMT, 5‑MeO‑DMT, 2C‑X, ibogaine, ayahuasca) are controlled under the DPR 309/1990 framework and may only be accessed in authorised clinical research or via tightly regulated medical channels when a licensed medicinal product exists. The one broadly available, reimbursed pharmaceutical in the psychedelic-adjacent space is esketamine (Spravato), which is classified for hospital use with national reimbursement (AIFA Class H); ketamine itself remains a controlled medicine used in hospital/clinical settings and in private off‑label practice for indications like anaesthesia and, in some private clinics, for treatment‑resistant depression but is not reimbursed by the SSN for that psychiatric indication. Citations to primary Italian regulatory acts and official Gazzetta/Ufficiale determinations are included inline below for each compound entry.
Compound-specific notes summarise what is realistically available through approved medical use, clinical research, exceptional access, or private care where the country report has verifiable information.
Compound Access
Currently classified as a strictly controlled substance under the Italian consolidated narcotics law framework (D.P.R. 9 October 1990, n. 309) and placed among the hallucinogens in the ministerial tables; there is no authorised medical/marketed psilocybin product reimbursed by the Servizio Sanitario Nazionale (SSN), and access is limited to approved clinical research under national/regional trial authorisations. # #
Compound Access
Currently classified under the national drug‑scheduling system (D.P.R. 309/1990; MDMA and related amphetamine‑type entactogens are listed among controlled substances). There is no authorised, reimbursed MDMA product for routine clinical use in Italy; clinical access requires participation in an authorised clinical trial and any therapeutic use outside trials would be unlawful. # #
Compound Access
Esketamine (Spravato) is the one psychedelic‑adjacent medicine that has been formally reclassified and placed within the reimbursability framework in Italy: AIFA issued Determina n. 334 (9 May 2022) reclassifying Spravato and specifying its use in combination with an SSRI or SNRI for adults with treatment‑resistant major depressive disorder (patients who failed ≥2 antidepressant treatments in the current episode); the Determina places Spravato in AIFA reimbursement class H and prescribes specific prescription and registry requirements (AIFA/ospedaliera schema and monitoring). #
Practical/regional implementation: after the national AIFA determination, Italian Regions have issued implementing decrees identifying authorised hospital/psychiatry centres allowed to prescribe and administer Spravato, requiring first administration in supervised hospital settings and use of AIFA therapy/monitoring registers; several regional health authorities (examples: Veneto) published decrees mapping authorised centres and reaffirming class H reimbursement and the requirement for hospital‑based prescribing and registry completion. #
Reimbursement, indications and payer rules: under Determina n. 334/2022 Spravato is reimbursed by the SSN in class H for the specific indication (treatment‑resistant major depressive disorder) and must be prescribed via the AIFA hospital prescribing form/register; supply and prescription modalities follow special prescription/regulatory tracks (ricetta ministeriale/registro AIFA) and are limited to accredited hospital or specialist psychiatric units. The national Determina text and published Gazzetta entry are the primary legal references for the exact indication and reimbursement class. #
Compound Access
Ketamine is a controlled medicinal substance in Italy (included within the DPR 309/1990 regulatory tables for controlled substances/medicines) but is widely used in licensed medical settings (anaesthesia, emergency medicine) and is also used off‑label in some private clinics for psychiatric indications (e.g., treatment‑resistant depression) under physician responsibility. The substance’s inclusion in the DPR tables imposes strict procurement, registry and prescription rules (special ordering/record‑keeping for controlled medicines), and its off‑label psychiatric use is generally not reimbursed by the SSN; availability and clinical pathways therefore differ by region and by institutional (public vs. private) setting. # #
Clinical / payer nuance: Because ketamine (the racemate) is not an authorised SSN‑reimbursed psychiatric medicine for depression, patients seeking repeated ketamine infusions for depression typically access treatment in private clinics (self‑pay) or as part of research protocols; where hospitals supply ketamine for anaesthesia/acute care this is covered as part of hospital care, but there is no SSN national tariff that reimburses repeated, scheduled ketamine infusions for psychiatric indications outside a formal programme or approved therapeutic pathway. #
Compound Access
Currently classified as a controlled psychotropic substance under the national scheduling and specifically referenced in recent ministerial updates (the Ministry of Health decree of 23 February 2022 inserted DMT and related plant preparations into the tables) and therefore has no authorised medical use outside approved clinical research. Access is limited to properly authorised clinical trials and import/handling under regulatory authorisations. #
Compound Access
Currently classified among controlled hallucinogenic/psychotropic substances under the DPR 309/1990 table updates (the Ministero della Salute and subsequent table update decrees have systematically placed novel and classical indole/tryptamine hallucinogens under control); there is no authorised medical or reimbursed pathway for 5‑MeO‑DMT, and access is restricted to regulated clinical research. # (standard national approach to novel hallucinogens)
Compound Access
Currently classified as a controlled substance in Italy with no recognised authorised medical indication or SSN reimbursement; use is unlawful outside of formally approved clinical trials or specific experimental authorisations. Access for addiction treatment historically occurs only in countries where national law permits it; in Italy, ibogaine remains controlled and not part of routine medical care. #
Compound Access
By ministerial decree (23 February 2022, published in G.U. 14 March 2022) the Italian Ministry of Health inserted Ayahuasca (ayahuasca extract, ground, powder) and its botanical sources Banisteriopsis caapi and Psychotria viridis, and component alkaloids (including DMT), into Tabella I of the DPR 309/1990 tables; as a result ayahuasca preparations are explicitly subject to the strict controls applicable to Table I substances and are not authorised for routine medical use—access is limited to authorised research or otherwise illegal. This ministerial change is the explicit legal basis for current enforcement and the classification of ayahuasca in Italy. #
Compound Access
Mescaline is listed among classical hallucinogens in the national tables under DPR 309/1990 and is controlled; there is no authorised medical/SSN‑reimbursed use in Italy and access is limited to approved clinical research. (Ministerial/regulatory tables and professional guidance list mescaline among hallucinogens subject to control.) # #
Compound Access
The 2C family and related designer phenethylamines fall under the broad controls exercised through DPR 309/1990 and subsequent ministerial table updates (new psychoactive designer phenethylamines are routinely inserted into the controlled tables); there is no authorised medical use or SSN reimbursement in Italy—access only via authorised clinical research when such trials exist. # #
Last updated 2 Mar 2026. Source links are drawn from citation annotations in the medical access and reimbursement guide.